CELLADON CORPORATION - COMMON STOCK. Daily Stock Analysis

Daily Stock Analysis, EIRL, CELLADON CORPORATION - COMMON STOCK, priceseries

CELLADON CORPORATION - COMMON STOCK. Daily Stock Analysis
Stock Information
Open
45.03
Close
43.26
High
45.03
Low
43.04
Previous Close
45.12
Daily Price Gain
-1.86
YTD High
59.01
YTD High Date
Jan 12, 2022
YTD Low
43.04
YTD Low Date
Mar 7, 2022
YTD Price Change
-14.06
YTD Gain
-24.53%
52 Week High
62.15
52 Week High Date
Sep 7, 2021
52 Week Low
43.04
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-9.42
52 Week Gain
-17.88%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 11. 2019
40.92
Nov 20. 2019
43.06
28 Trading Days
5.24%
Link
LONG
May 22. 2020
34.08
Jun 9. 2020
37.11
11 Trading Days
8.91%
Link
LONG
Nov 3. 2020
42.51
Dec 11. 2020
48.41
27 Trading Days
13.88%
Link
Company Information
Stock Symbol
EIRL
Exchange
NasdaqGM
Company URL
http://www.eigerbio.com
Company Phone
650-279-9845
CEO
David A. Cory
Headquarters
California
Business Address
350 CAMBRIDGE AVE, SUITE 350, PALO ALTO, CA 94306
Sector
-
Industry Category
-
Industry Group
-
CIK
0001305253
About

Eiger BioPharmaceuticals, Inc. is a clinical-stage company, which engages in the research, development, and commercialization of biopharmaceutical products. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.

Description

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. It portfolio of products include Sarasar, an indication for the hepatitis delta virus infection; Exendin, which is used for the treatment of hypoglycemia associated with bariatric surgery; and Bestatin that is used for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. The company was founded in 2008 and is headquartered in Palo Alto, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading